Progressus Therapy Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Progressus Therapy's estimated annual revenue is currently $163.8M per year.(i)
  • Progressus Therapy's estimated revenue per employee is $140,000

Employee Data

  • Progressus Therapy has 1170 Employees.(i)

Progressus Therapy's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Marketing OfficerReveal Email/Phone
3
VP- Finance - Revenue Cycle -HRReveal Email/Phone
4
VP School-based Applied Behavior AnalysisReveal Email/Phone
5
Regional VPReveal Email/Phone
6
Director Client PartnershipsReveal Email/Phone
7
Senior Director Clinical QualityReveal Email/Phone
8
Regional DirectorReveal Email/Phone
9
Northeast Area DirectorReveal Email/Phone
10
Area DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$18.5M16828%N/AN/A
#2
$84.4M67557%N/AN/A
#3
$2.8M356%N/AN/A
#4
$24M21811%N/AN/A
#5
$5.8M0N/AN/AN/A
#6
$137.6M9833%N/AN/A
#7
$82.4M6596%N/AN/A
#8
$23.2M211-2%N/AN/A
#9
$45.6M3656%N/AN/A
#10
$27.5M25010%N/AN/A
Add Company

What Is Progressus Therapy?

keywords:N/A

N/A

Total Funding

1170

Number of Employees

$163.8M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Progressus Therapy News

2022-04-06 - NA Proactive news snapshot: Recruiter.com, Montero Mining and Exploration, Zeb Nickel, Audacious, Nomad Royalty Company, Fobi AI, Revive Therapeutics UPDATE...

... halted their previous daily oral antiretroviral therapy regimens. ... of Progressus' market responsive hydrogen products.

2022-04-06 - NA Proactive news snapshot: Recruiter.com, Montero Mining and Exploration, Zeb Nickel, Audacious, Nomad Royalty Company, Fobi AI, Revive Therapeutics UPDATE...

... halted their previous daily oral antiretroviral therapy regimens. ... of Progressus' market responsive hydrogen products.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$237.5M11700%N/A
#2
$434.8M1172-10%N/A
#3
$345.2M1174N/AN/A
#4
$373.1M11748%N/A
#5
$288.6M117821%N/A